Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to generate pharmacokinetic and pharmacodynamic data to identify the
safe-effective dose of empagliflozin in children and adolescents aged 10 to less than 18
years with type 2 diabetes mellitus.